Foresee Pharmaceuticals Co., Ltd. is a Taiwan-based company mainly engaged in the research and development of new pharmaceuticals. The Company's main products include prostate cancer treatment product FP-001 and asthmatic/chronic obstructive pulmonary disease treatment product FP-025. It also engages in new pharmaceuticals clinic trial business.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-18	78.40 NT$	-0.51%	503,472
26-06-17	78.80 NT$	-0.25%	77,919
26-06-16	79.00 NT$	+0.89%	87,618
26-06-15	78.30 NT$	-1.01%	118,233
26-06-12	79.10 NT$	+0.13%	105,087

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

78.40TWD

Average target price

153.00TWD

Spread / Average Target

+95.15%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

End-of-day quote Taipei Exchange Other stock markets 2026-06-18			5-day change	1st Jan Change
78.40 ^TWD	-0.51%		-0.88%	-2.73%

06-08	Foresee Pharmaceuticals Oral ALDH2 Activator Mirivadelgat Enters Clinical Testing in Parkinson's Disease in the SLEIPNIR Phase 2A Platform Trial	CI
05-27	Foresee Pharmaceuticals Completes Casppian Phase 3 Study and Confirms Topline Results for FP-001 42 Mg in Central Precocious Puberty	CI

Market Cap	12.35B 390M 340M 315M 295M 553M 36.82B 557M 3.74B 1.45B 18.12B 1.46B 1.43B 62.93B	P/E 2024	-9.84x	P/E 2025	-14.1x
Enterprise Value	12.1B 382M 333M 309M 289M 542M 36.08B 545M 3.66B 1.42B 17.76B 1.44B 1.4B 61.67B	EV / Sales 2024	26x	EV / Sales 2025	28.9x
Free-Float	54.53%	Yield 2024 *	-	Yield 2025	-

06-08	Foresee Pharmaceuticals Oral ALDH2 Activator Mirivadelgat Enters Clinical Testing in Parkinson's Disease in the SLEIPNIR Phase 2A Platform Trial	CI
05-27	Foresee Pharmaceuticals Completes Casppian Phase 3 Study and Confirms Topline Results for FP-001 42 Mg in Central Precocious Puberty	CI
05-13	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-13	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-06	Foresee Pharmaceuticals Announces Positive ChHMP Opinion Recommending Approval Of CAMCEVI 21 Mg 3-Month Strength In European Union	CI
02-04	Foresee Pharmaceuticals Co., Ltd. Receives the Fourth Positive Recommendation from the DSMB to Continue the Casppian Ph3 Study, for Central Precocious Puberty	CI
12-24	Foresee Pharmaceuticals Announces Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust Lh Suppression with 6-Month Dosing Interval of Leuprolide Mesylate	CI
11-13	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-29	Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI ETM for the Treatment of Advanced Prostate Cancer	CI
25-08-12	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-07-30	Foresee Pharmaceuticals Co., Ltd. announced that it expects to receive TWD 400 million in funding	CI
25-06-17	Foresee Completes Phase 3 CASPPIAN Trial Enrollment For Central Precocious Puberty	RE
25-06-17	Foresee Pharmaceuticals Announces Complete Enrollment of its Phase 3 Casppian Trial for Patients with Central Precocious Puberty	CI

24-08-12	Foresee Pharmaceuticals Announces Several New Developments Related to its SIF Long-Acting Injectable (LAI) Technologies - Solidifying its Position as a Leader in Complex Long-Acting Injectable Products	AQ
24-04-02	Foresee Pharmaceuticals Receives Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide Injectable Emulsion for the Treatment of CPP	AQ
23-10-31	Foresee Pharmaceuticals to Present at the American Heart Association Annual Meeting Focusing on its ALDH2 activator FP-045 in Pulmonary Hypertension Associated with Interstitial Lung Disease	AQ
23-10-02	Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium	AQ
23-10-02	Foresee Pharmaceuticals Announces Publication of Preclinical Data in Nature Communications	AQ

Foresee Pharmaceuticals Co., Ltd. Stock

Stocks

6576

TW0006576002

Biotechnology & Medical Research

Valuation: Foresee Pharmaceuticals Co., Ltd.

Chart: Foresee Pharmaceuticals Co., Ltd.

Latest news : Foresee Pharmaceuticals Co., Ltd.

Press Releases: Foresee Pharmaceuticals Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Foresee Pharmaceuticals Co., Ltd.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

1 day	-0.51%
1 week	-0.76%
Current month	+1.82%
1 month	-4.16%
6 months	-1.26%
Current year	-2.73%

1 week	78.3	82.4
1 month	75.3	82.4
Current year	75.1	88.3
1 year	61.6	93.7
3 years	57.7	107.5
5 years	57.7	141
10 years	35.1	141

Manager	Title	Age	Since
Benjamin Chien CEO	Chief Executive Officer	-	2013-02-07
Yu Hua Li CTO	Chief Tech/Sci/R&D Officer	-	2015-07-08
Max Chan DFI	Director of Finance/CFO	58	2019-10-06

Director	Title	Age	Since
Chang Jen Yan BRD	Director/Board Member	-	2013-01-09
Sheng Lee Yi BRD	Director/Board Member	-	2013-01-09
George Lee BRD	Director/Board Member	75	2015-08-02

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FORESEE PHARMACEUTICALS CO., LTD.	-0.51%	-0.76%	+20.43%	-5.77%	391M
LONZA GROUP AG	+1.44%	+1.71%	-10.63%	-9.16%	42.75B
REVOLUTION MEDICINES, INC.	+3.31%	+5.93%	+308.19%	+562.02%	34.65B
BEONE MEDICINES AG	+2.84%	+2.14%	+6.87%	+34.93%	30.03B
IQVIA HOLDINGS INC.	-1.70%	-7.54%	+8.51%	-22.34%	28B
CELLTRION, INC.	-1.90%	+2.47%	+10.18%	+18.13%	24.83B
ASCENDIS PHARMA A/S	-0.14%	+5.86%	-	-	14.34B
MEDPACE HOLDINGS, INC.	+0.68%	-1.53%	+52.04%	+107.47%	13.14B
EUROFINS SCIENTIFIC SE	-0.57%	-2.43%	+5.18%	+4.20%	12.61B
IONIS PHARMACEUTICALS, INC.	-0.26%	+1.15%	+100.27%	+80.69%	12.25B
Average	+0.32%	+0.41%	+55.67%	+85.57%	21.3B
Weighted average by Cap.	+0.77%	+0.91%	+64.97%	+112.80%

	2024	2025
Net sales	419M 13.23M 11.53M 10.68M 10M 18.75M 1.25B 18.87M 127M 49.11M 614M 49.65M 48.59M 2.13B	431M 13.63M 11.88M 11M 10.3M 19.32M 1.29B 19.43M 131M 50.59M 633M 51.15M 50.05M 2.2B
Net income	-1.08B -34.15M -29.78M -27.58M -25.82M -48.42M -3.22B -48.72M -327M -127M -1.59B -128M -125M -5.51B	-883M -27.9M -24.33M -22.53M -21.09M -39.56M -2.63B -39.8M -267M -104M -1.3B -105M -102M -4.5B
Net Debt	-1.11B -34.97M -30.49M -28.24M -26.44M -49.58M -3.3B -49.88M -335M -130M -1.62B -131M -128M -5.64B	-248M -7.83M -6.83M -6.32M -5.92M -11.1M -739M -11.17M -74.99M -29.06M -364M -29.38M -28.75M -1.26B